Forgot Password?
Return to Course Listing

CME: Closing the gap in the treatment of constipation-predominant irritable bowel syndrome (IBS-C): From recognition to treating the patient


Activity Description / Statement of Need:

In this online, self-learning activity:

Irritable bowel syndrome (IBS) is among the most common disorders seen by primary care as well as gastroenterology specialty clinics. Patients with IBS usually present with chronic abdominal pain and altered bowel habit, in the absence of any other disease to cause these sorts of symptoms. The disorder is associated with annual healthcare expenditures of $20 billion and significant costs in lost work productivity and health-related quality-of-life.

Although not uncommon, there is still much that is unknown about IBS-C, and its diagnosis has largely remained dependent on symptom-based criteria with their share of limitations.

This activity has been designed to update HCPs’ knowledge of IBS-C and to improve their competence and performance in treating it.

Target Audience:

The following HCPs: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in gastroenterology; and any other HCPs with an interest in or who clinically encounter patients with IBS-C.

Commercial Support Disclosure: This program is supported by an educational grant from Salix, a subsidiary of Bausch Health.

This activity is free of charge.

Release Date: August 18, 2021 -- Expiration Date: August 18, 2023

Faculty: Nipaporn Pichetshote, MD


Faculty introduction, disclosures

Introduction content and review of IBS-C

  • Prevalence
  • Subtypes
  • IBS-C clinical features, presentation, diagnostic criteria, and clinical evaluation

· Distinction between IBS-C & -M

Treatment of IBS-C

  • Clinical trial findings and guideline remarks
  • Present and investigational pharmacotherapy, including symptomatic control

·  Osmotic laxatives

·  Guanylate cyclase agonism

·  Chloride channel activation

·  5-hydroxytryptamine (serotonin) 4 receptor agonism

  • Non-pharmacologic management
  • Barriers to optimal care in patients with IBS-C
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the clinical presentation and approach to diagnosing IBS-C.
  • Identify present and emerging treatment modalities for the management of IBS-C.
  • Formulate a treatment plan for a patient with IBS-C.


ACCME Activity #201759863


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Nipaporn Pichetshote, MD, Associate Director, GI Motility Program, Cedars Sinai, has received financial compensation for Grant Research from Bausch Health Ireland Limited. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will not discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Salix, a subsidiary of Bausch Health.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies

Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?

Medical and nutritional management of eosinophilic esophagitis in adolescents and adults: Therapeutic updates and best practices